GE invests in cardiovascular IVD with CardioDx alliance
This article was originally published in Clinica
GE Healthcare has invested $5m CardioDx, a privately-held company specialising in cardiovascular genomic diagnostics. The move is consistent with the company's strategy to expand out of in vivo and into in vitro diagnostics. The news, announced today, also marks the first investment for GE's $250m Healthymagination fund, which was launched last year as part of a $6bn initiative to improve and increase healthcare access.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.